4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry and is headquartered in Antwerp, Belgium with about 62 employees. Its market capitalization is roughly $737 million. In the fiscal year ended 2025-12-31, AGMB reported €0M in revenue and (€62M) in net income.
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | €0M | €0M | €0M | €0M |
| Operating Income (EBIT) | (€59M) | (€48M) | (€31M) | (€23M) |
| Net Income | (€62M) | (€46M) | (€11M) | (€8M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | €0M | €0M | €0M |
| Operating Income (EBIT) | (€16M) | (€15M) | (€12M) |
| Net Income | (€17M) | (€18M) | (€12M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €154M | €206M | €171M | €101M | — |
| Total Liabilities | €23M | €18M | €20M | €35M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AGMB viewer.
About TickerBase · Data methodology & sources · Privacy · Terms